Securing Medicare coverage and launching our first TrueMRD Test are significant milestones for Veracyte and important steps in enabling access to our MRD testing platform,” said Marc Stapley, Veracyte ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder Genomic ...

The Decipher Bladder test identifies aggressive bladder cancer, aiding in treatment decisions beyond initial clinical staging. Non-luminal tumors in NMIBC show higher upstaging rates to MIBC and ...

The test is covered for recurrence monitoring following treatment with curative intent in individuals with  muscle-invasive bladder cancer and will be available starting June 1.

Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions and ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...

Roche RHHBY announced that the FDA has approved a label expansion for Tecentriq (atezolizumab) and Tecentriq Hybreza ...

Groundbreaking study published in The Journal of Molecular Diagnostics paves the way for noninvasive screening tools that improve patient comfort and outcomes Bladder cancer remains a major clinical ...

The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with ...